A systematic review: The management and outcomes of ileal pouch strictures.

A systematic review: The management and outcomes of ileal pouch strictures. J Crohns Colitis. 2017 Nov 16;: Authors: Segal JP, Worley G, Adegbola SO, Sahnan K, Tozer P, Lung PFC, Faiz OD, Clark SK, Hart AL Abstract Background: Restorative proctocolectomy with ileal pouch-anal anastomosis removes the diseased tissue in ulcerative colitis but also allows gastrointestinal continuity and stoma-free living. Pouch strictures are a complication with a reported incidence of 5-38%. The three areas where pouch strictures occur are in the pouch inlet, mid-pouch and pouch-anal anastomosis. Aim: To undertake a…

Read More

The proton-activated receptor GPR4 modulates intestinal inflammation.

The proton-activated receptor GPR4 modulates intestinal inflammation. J Crohns Colitis. 2017 Nov 09;: Authors: Wang Y, de Vallière C, Imenez Silva PH, Leonardi I, Gruber S, Gerstgrasser A, Melham H, Weber A, Leucht K, Wolfram L, Hausmann M, Krieg C, Thomasson K, Boyman O, Frey-Wagner I, Rogler G, Wagner CA Abstract BACKGROUND AND AIMS: During active inflammation tissue intraluminal intestinal pH is decreased in patients with inflammatory bowel disease (IBD). Acidic pH may play a role in IBD pathophysiology. Recently, proton sensing G-protein coupled receptors were identified, including GPR4, OGR1…

Read More

Exploration of predictive biomarkers of early infliximab response in acute severe colitis: A prospective pilot study.

Exploration of predictive biomarkers of early infliximab response in acute severe colitis: A prospective pilot study. J Crohns Colitis. 2017 Nov 07;: Authors: Beswick L, Rosella O, Rosella G, Headon B, Sparrow MP, Gibson PR, van Langenberg DR Abstract Background: Outcomes of acute severe ulcerative colitis (ASUC) appear dependent on early intervention with the first and/or further infliximab(IFX) doses, though parameters to guide decision-making remain uncertain. Aim: To assess whether serum/faecal IFX levels and inflammatory biomarkers early post-IFX dose can predict ASUC outcomes. Methods: This prospective pilot study consecutively recruited…

Read More

Corrigendum: Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management.

Corrigendum: Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management. J Crohns Colitis. 2017 Oct 21;: Authors: Harbord M, Eliakim R, Bettenworth D, Karmiris K, Katsanos K, Kopylov U, Kucharzik T, Molnár T, Raine T, Sebastian S, de Sousa HT, Dignass A, Carbonnel F, European Crohn’s and Colitis Organisation [ECCO] PMID: 29088340 [PubMed – as supplied by publisher] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/29088340?dopt=Abstract

Read More

Faecal Calprotectin and UCEIS Predict Short-term Outcomes in Acute Severe Colitis: Prospective Cohort Study.

Faecal Calprotectin and UCEIS Predict Short-term Outcomes in Acute Severe Colitis: Prospective Cohort Study. J Crohns Colitis. 2017 Oct 27;11(11):1309-1316 Authors: Jain S, Kedia S, Bopanna S, Sachdev V, Sahni P, Dash NR, Pal S, Vishnubhatla S, Makharia G, Travis SPL, Ahuja V Abstract Background and Aims: Early objective markers for failure of intravenous[iv] corticosteroid for acute severe colitis [ASC] can avoid delay in rescue therapy or colectomy. We investigated faecal calprotectin [FC], C-reactive protein [CRP], and endoscopy using the ulcerative colitis endoscopic index of severity [UCEIS] as predictors of…

Read More

Vedolizumab in IBD – lessons from real-world experience; a systematic review and pooled analysis.

Vedolizumab in IBD – lessons from real-world experience; a systematic review and pooled analysis. J Crohns Colitis. 2017 Oct 25;: Authors: Engel T, Ungar B, Yung DE, Ben-Horin S, Eliakim R, Kopylov U Abstract Background: Vedolizumab (VDZ) is an anti-integrin monoclonal antibody effective in ulcerative colitis (UC) and Crohn’s disease (CD). Several real-world experience (RWE) studies with VDZ were published to date. The aim of this systematic review was to summarize the available real-life experience with VDZ. Methods: We performed a systematic review of the available RWE studies of VDZ…

Read More

Anti-TNF re-induction is as effective, simpler and cheaper compared with dose-interval shortening for secondary loss of response in Crohn’s disease.

Anti-TNF re-induction is as effective, simpler and cheaper compared with dose-interval shortening for secondary loss of response in Crohn’s disease. J Crohns Colitis. 2017 Oct 25;: Authors: Srinivasan A, Vasudevan A, McFarlane A, Sparrow MP, Gibson PR, van Langenberg D Abstract Background and Aims: The optimal duration of dose-intensified therapy following secondary loss of response (LOR) to anti-TNF therapy remains unclear. Anti-TNF re-induction involves a finite period of intensified therapy and may be a cost-effective means of re-capturing response. This study aimed to compare the efficacy, durability and cost of anti-TNF…

Read More

Ustekinumab drug levels in maternal and cord blood in a woman with Crohn’s disease treated until 33 weeks gestation.

Ustekinumab drug levels in maternal and cord blood in a woman with Crohn’s disease treated until 33 weeks gestation. J Crohns Colitis. 2017 Oct 16;: Authors: Rowan CR, Cullen G, Mulcahy HE, Keegan D, Byrne K, Murphy DJ, Sheridan J, Doherty GA Abstract A 35-year old woman with ileocolonic, perianal and vulval Crohn’s disease was treated with subcutaneous ustekinuamb (USK) throughout pregnancy. Dose intervals were shortened from 6-weekly to 4-weekly to maintain clinical remission. The last dose of USK was administered at 33 weeks gestation and a healthy baby boy…

Read More

Transcriptomic Landscape of Treatment – Na├»ve Ulcerative Colitis.

Related Articles Transcriptomic Landscape of Treatment – Naïve Ulcerative Colitis. J Crohns Colitis. 2017 Oct 10;: Authors: Taman H, Fenton CG, Hensel IV, Anderssen E, Florholmen J, Paulssen RH Abstract Background and Aims: Ulcerative colitis (UC) is a chronic inflammatory disease that effects the gastrointestinal tract and is considered one of the most prominent and common forms of inflammatory bowel disease (IBD). This study aimed to define and describe the entire transcriptomic landscape in a well-stratified, treatment-naïve UC patient population compared to control patients by using next-generation technology, RNA-Seq. Methods:…

Read More

Genital granulomatosis in male and female patients with Crohn`s disease: clinical presentation and treatment outcomes.

Genital granulomatosis in male and female patients with Crohn`s disease: clinical presentation and treatment outcomes. J Crohns Colitis. 2017 Sep 27;: Authors: Dederichs F, Iesalnieks I, Sladek M, Tzivinikos C, Hansen R, Muñoz C, Pavli P, Cavicchi MN, Abitbol V, Rahier JF, Vavricka SR, Katsanos K, Domènech E, ECCO-CONFER investigators Abstract Background: Genital granulomatosis (GG) is a metastatic form of Crohn’s Disease (CD), characterized by granulomatous inflammation of the genital skin without contact to the gastrointestinal tract. Little is known about GG as most publications are case reports or small…

Read More
<< Go Back